Life Sciences Tools and Services
Company Overview of Gentris LLC
Gentris LLC provides pharmacogenomic (PGx) testing and biorepository services. Its PGx testing services include clinical genotyping assays, gene expression assays, next generation sequencing, tumor profiling, custom assay development and validation, clinical sample logistics, nucleic acid extraction from multiple tissue types, and biostorage and sample management services. The company’s services also include biomarker solutions, such as pharmacogenomics applying, genotyping, generation expression, next gen sequencing, bioinformatics, custom assay design, and consulting services; and integrated biorepository services, including biobanking, sample logistics, sample storage systems, and nucleic...
133 Southcenter Court
Morrisville, NC 27560
Founded in 2001
Key Executives for Gentris LLC
Chief Executive Officer, President and Director
Chief Scientific Officer and Vice President of Global Scientific Operations
Vice President of Diagnostics & Marketing
Compensation as of Fiscal Year 2015.
Gentris LLC Key Developments
Gentris Corporation Reports Unaudited Earnings Results for Second Quarter Ended June 30, 2014
Aug 14 14
Gentris Corporation reported unaudited earnings results for second quarter ended June 30, 2014. For the quarter, on non-GAAP basis, the company reported revenue was $1,719.1 million. Loss from operations was $1,324.9 million. Loss before income taxes was $509.6 million. Net loss was $509.6 million.
Gentris Corporation Announces Executive Appointments
Feb 20 14
Gentris Corporation announced the addition of Dr. Heath Knight as vice president, corporate development and Mr. Joseph Kessler, as chief operating officer. These two executives join the executive leadership team as the company anticipates its next phase of growth. Heath Knight, Ph.D., will lead business development, sales, and marketing. Her focus will be driving further expansion of the company's genomic testing and bio-repository services in domestic and international markets. A key focus will be in China where the company opened its first international facility in November, 2013. Dr. Knight was previously with Gentris as vice president of sales and marketing and left in 2008 to join Third Wave Technologies as executive director of genomic services and general manager of the newly formed pharmacogenomic Services business unit. She was recently strategic director of companion diagnostics for LabCorp's Clinical Trials. Over the past 15 years, Dr. Knight has held senior management positions in business development and sales as well laboratory operations in leading specialty genomic testing providers. She earned a Ph.D. degree in Human Genetics from the Medical College of Virginia and completed postdoctoral training at Baylor College of Medicine and the Mayo Clinic. Joseph Kessler, M.S., will head operations at Gentris' two laboratories, the company headquarters located in Research Triangle Park, NC and the newly opened testing and storage facility in Shanghai, China. Mr. Kessler has over 25 years leadership experience in clinical research and operations. Mr. Kessler joins Gentris from DaVita labs where he was senior director of laboratory operations and was responsible for oversight of their CAP/CLIA clinical testing laboratory and sample repository services.
Gentris Corporation Opens New Genomic Biomarker Laboratory in China
Nov 20 13
Gentris(R) Corporation announced that it has opened a new genomic biomarker testing and biorepository services laboratory in Shanghai, China. Gentris Shanghai will provide GCLP-compliant testing and biobanking services for global pharmaceutical clients under international standards. Gentris Shanghai will solve a critical need for pharmacogenomic (PGx) testing and clinical sample storage under international standards in China.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|